Results 21 to 30 of about 82,231 (299)

Buying time: Drug repurposing to treat the host in COVID‐19H

Pharmacology Research & Perspectives, 2020
In 2016 Fedson stated …. “For almost two decades, leading scientists and health officials have warned that we must prepare for a potentially devastating global pandemic of an infectious disease. Initial concern was focused on …H5N1….
Jennifer H. Martin, Julian Clark, Richard Head   +2 more
doaj   +1 more source

Synergistic drug combinations from electronic health records and gene expression. [PDF]

, 2016
ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William, Daugherty, Aaron C, Desai, Manisha, Farrington, Carl, Gomez, Scarlett L, Hastie, Trevor, Kenkare, Pragati, Kurian, Allison W, Lim, Michael, Low, Yen S, Mathur, Maya, Radin, Andrew A, Schroeder, Elizabeth A, Seto, Tina, Shah, Nigam H, Sirota, Marina, Sledge, George W, Thompson, Caroline A, Weber, Susan, Yu, Peter P   +19 more
core   +2 more sources

A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

Clinical Epigenetics, 2023
Background N-methyl-2-pyrrolidone (NMP) is an epigenetically active chemical fragment and organic solvent with numerous applications including use as a drug-delivery vehicle. Previously considered biologically inert, NMP demonstrates immunomodulatory and
Jake Shortt, Peter Galettis, Chan Y. Cheah, Joanne Davis, Mandy Ludford-Menting, Emma K. Link, Jennifer H. Martin, Rachel Koldej, David Ritchie   +8 more
doaj   +1 more source

Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment [PDF]

, 2020
BACKGROUND: Docetaxel chemotherapy in prostate cancer has a modest impact on survival. To date, efforts to develop combination therapies have not translated into new treatments. We sought to develop a novel therapeutic strategy to tackle chemoresistant
Dufès, Christine, Hewit, Kay, James, Daniel, Leung, Hing, Munnings-Tomes, Sophie, Patel, Rachana, Rushworth, Linda, Shanks, Emma, Somani, Sukrut, Straube, Anne   +9 more
core   +3 more sources

Drug Repurposing: Far Beyond New Targets for Old Drugs [PDF]

, 2012
Repurposing drugs requires finding novel therapeutic indications compared to the ones for which they were already approved. This is an increasingly utilized strategy for finding novel medicines, one that capitalizes on previous investments while ...
B Flachner, B Munos, BK Lin, CG Wermuth, CR Chong, D Curley, D Schuster, D Shigemizu, F Briansó, F Prinz, FS Collins, G Steinbach, GMS Silva Da, J Mestres, J Mestres, J Mestres, J. Mestres, JO Yang, K Sanderson, K Seibert, M Campillos, M Cases, MA Lindsay, MJ Keiser, P Cuatrecasas, RF Service, RG Kurumbail, RT Strachan, S Zhao, SH Sleigh, SL Kinnings, T Kawamori, T. I. Oprea, TD Warner, TI Oprea, TI Oprea, TI Oprea, TI Oprea, TT Ashburn, W Weber, WL Lipworth   +40 more
core   +1 more source

Patient-specific data fusion for cancer stratification and personalised treatment [PDF]

, 2016
According to Cancer Research UK, cancer is a leading cause of death accounting for more than one in four of all deaths in 2011. The recent advances in experimental technologies in cancer research have resulted in the accumulation of large amounts of ...
Gligorijević, V, Malod-Dognin, N, Pržulj, N   +2 more
core   +1 more source

Klotho pathways, myelination disorders, neurodegenerative diseases, and epigenetic drugs [PDF]

, 2020
In this review we outline a rationale for identifying neuroprotectants aimed at inducing endogenous Klotho activity and expression, which is epigenetic action, by definition. Such an approach should promote remyelination and/or stimulate myelin repair by
Chen, Xiaohong, Faller, Douglas V., Glavas, Ioannis P., Harpp, David N., Kanara, Iphigenia, Kodukula, Krishna, Mavrakis, Anastasios N., Moos, Walter H., Pernokas, Julie, Pernokas, Mark, Pinkert, Carl A., Powers, Whitney R., Sampani, Konstantina, Steliou, Kosta, Vavvas, Demetrios G., Zamboni, Robert J.   +15 more
core   +1 more source

Repurposing drugs to target nonalcoholic steatohepatitis [PDF]

, 2019
Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage.
Pirola, Carlos José, Sookoian, Silvia Cristina   +1 more
core   +1 more source

Drug Repurposing

Citation: 'drug repurposing' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12648 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
Phil Ambery, Adrian Kilcoyne, Daniel O’Connor   +2 more
  +6 more sources

Repurposing – second life for drugs [PDF]

Pharmacia, 2022
Drug repurposing refers to finding new indications for existing drugs. The paradigm shift from traditional drug discovery to drug repurposing is driven by the fact that new drug pipelines are getting dried up because of mounting Research &amp ...
Porkodi Ayyar, Umamaheswari Subramanian
doaj   +3 more sources